| Similar Articles |
|---|
 |
The Motley Fool
July 11, 2007
Brian Orelli |
Everybody Loves RNAi Roche is the latest firm to (over)pay for the hottest new drug technology. Alnylam announced that it licensed some of its intellectual property to Roche for $331 million. Investors, take note.   |
The Motley Fool
November 30, 2010
Brian Orelli |
RNAi Is On Sale The novel technology looks more promising at these prices. |
The Motley Fool
January 9, 2009
Brian Orelli |
Alnylam Holds Hands With a New Fella Is big pharma turning up its nose at RNAi drugs? |
The Motley Fool
September 24, 2010
Brian Orelli |
So Long and Thanks for All the Drug Candidates Alnylam and Novartis end their five-year partnership. |
The Motley Fool
September 28, 2007
Brian Orelli |
RNAi Doesn't Kill Mice After All From Merck, to AstraZeneca, to Novartis, big pharma continues to pump hundreds of millions of dollars into unproven RNAi technology. Investors, take note. |
The Motley Fool
April 27, 2011
Brian Orelli |
Don't Get Pumped Up About Pumping It In Medtronic and Eli Lilly team up against Parkinson's. |
The Motley Fool
February 29, 2008
Brian Orelli |
RNAi Works -- Maybe Alnylam presents the first proof of concept that RNAi works in humans, but where's the proof that it cures a disease? |
The Motley Fool
September 20, 2007
Brian Orelli |
A Pharma Divorce, and Good Riddance Merck and Alnylam call it quits. The only real question is why the two didn't end the partnership months ago. What will it mean to investors? |
The Motley Fool
May 18, 2007
Mike Havrilla |
Ample Opportunities for Alnylam The biotech's RNAi pipeline and cutting-edge technology make it a prime takeover candidate. Investors, take note. |
The Motley Fool
May 28, 2008
Brian Orelli |
A Partnership of Habitual Deal Makers A partnership between these two companies gives Alnylam another $150 million to pad its coffers with and Takeda a call option on an unproven but promising set of drugs. |
The Motley Fool
February 9, 2006
Jason Mac Gurn |
RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals... |
The Motley Fool
June 9, 2009
Brian Orelli |
Alnylam Lays Down a Sacrifice Bunt RNAi is still an unproven technology, and there's plenty of chances for it to strike out. |
The Motley Fool
February 28, 2011
Brian D. Pacampara |
Next-Generation Drug Technologies Battle It Out Alnylam and Sangamo BioSciences have different ways to manipulate proteins to fight disease. |
Bio-IT World
December 15, 2004
Nancy Weil |
Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic. |
The Motley Fool
September 10, 2007
Brian Orelli |
Double Your RNA Pleasure Alnylam and ISIS join together to work on microRNAs. Their joint venture, called Regulus Therapeutics, combines their intellectual property in an effort to advance this new technology. Investors should take note. |
Bio-IT World
July 15, 2003
Malorye Branca |
Silence Is Golden RNA interference's scientific, therapeutic, and economic potential is unquestionable, but some sticky questions still remain. |
The Motley Fool
August 15, 2006
Ralph Casale |
Sirna Battles Genes Gone Bad Pharmaceutical start-up Sirna Therapeutics tests drugs to silence rogue genes. Investors, while drugs based on RNA interference may have the potential to become the next big thing in biotechnology, they're still a long, long way from becoming FDA-approved, marketable entities. |
The Motley Fool
May 20, 2009
Brian Orelli |
Joining to Treat, and Beat, Diabetes Medical-device maker Medtronic and drugmaker Eli Lilly are teaming up to co-promote the companies' diabetes products to doctors and patients. |
Bio-IT World
December 15, 2004
David A. Bumcrot |
Identifying RNAi Drug Candidates Breakthroughs in understanding RNA's extensive role in essential cellular processes have opened up the potential for a whole new class of drugs based on RNAi. |
Bio-IT World
November 2006
Kevin Davies |
Merck's $1.1 Billion Bet on RNAi As if the 2006 Nobel Prize in Medicine or Physiology wasn't validation enough, Merck's acquisition of biotech firm Sirna for $1.1 billion last month offered evidence of the commercial implications of RNA interference gene-silencing technology. |
The Motley Fool
November 18, 2010
Travis Hoium |
Alnylam Pharmaceuticals Shares Plunged: What You Need to Know Roche Holding AG announced it would end its partnership with Tekmira Pharmaceuticals, dragging Alnylam down in the fray. This move affects research for RNAi therapeutics, a focus for Alnylam. |
Bio-IT World
December 15, 2004
Zachary Zimmerman |
Silence Is Golden Life Science Insights believes that RNAi therapeutics will dramatically affect the pharmaceutical and healthcare industries, becoming the next major class of therapeutics, joining small molecules, proteins, and monoclonal antibodies. |
The Motley Fool
November 6, 2006
Ralph Casale |
Validation for a Biotechnology Firm? How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals. With the recent run-up in share price due to the Merck offer for Sirna, investors should wait for a better price before speculating on Alnylam. |
The Motley Fool
October 5, 2006
Ralph Casale |
RNAi: Nobel Prize-Winning Biotechnology While drugs based on RNAi knockdown technology may have the potential to become the next big thing in biotechnology, they are still a long way from becoming FDA-approved marketable entities. But it's never too soon to start keeping an eye on the future. Investors, take note. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
The Motley Fool
April 27, 2011
Arundhati Parmar |
Medtronic and Eli Lilly Join Hands to Combat Parkinson's Disease The partnership aims to research and develop a new approach to treating the debilitating disease. |
BusinessWeek
February 26, 2007
Gene G. Marcial |
CytRx Can 'Silence' Genes That Cause Disease Since October, shares of CytRx have more than doubled as investors zeroed in on its RNA interference technology that targets diabetes, obesity, and ALS. |
The Motley Fool
September 14, 2007
Brian Orelli |
J&J's Expensive RNA Purchase Johnson & Johnson sets up a collaboration with Isis Pharmaceuticals to develop compounds to treat diabetes. Investors take note. |
The Motley Fool
November 13, 2006
Jack Uldrich |
Arrowhead: A Long-Term RNAi Play? Its majority stake in Calando Pharmaceuticals could pay dividends. Investors would be wise to continue to watch this company and wait until clinical trials have advanced to a more mature stage before considering an investment. |
The Motley Fool
March 24, 2008
Brian Orelli |
Alnylam Authorizes Again The pharmaceutical's latest patent-licensing deal won't be immediately lucrative. |
The Motley Fool
October 4, 2007
Billy Fisher |
Isis Keeps Cholesterol Down, Stock Prices Up Isis Pharmaceuticals reports positive phase 2 results for a cholesterol treatment. The company continues to show progress with its impressive pipeline of 17 other development-stage drugs. Investors, take note. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
Chemistry World
March 21, 2010
Simon Hadlington |
Nanoparticles successfully deliver RNA interference in cancer patients The system aims to exploit the phenomenon of RNA interference, where short sequences of double-stranded RNA, called small interfering RNA or siRNA, can trigger the disruption of the manufacture of certain proteins in a cell. |
Pharmaceutical Executive
July 30, 2007 |
Tomorrow's Drugs A look at the seven top therapies and technologies vying to deliver the next generation of drugs. |
Bio-IT World
March 2006 |
News Blast Merck/Phase Forward... Curbing a Pandemic... Focused Trials... Collaboration... |
Managed Care
November 2003
Thomas Morrow |
Making Sense of Antisense and Interference Treatments that interfere with protein synthesis at the cellular level will soon be debated in medical policy committee meetings. |
The Motley Fool
March 2, 2011 |
Fool Q&A: Medtronic CFO Gary Ellis The medical-device maker's chief financial officer talks R&D, "One Medtronic," and growth in emerging markets. |
Chemistry World
June 19, 2015
Rebecca Trager |
Alnylam accuses Dicerna of stealing trade secrets The US biopharmaceutical company Alnylam has filed a 'trade secret misappropriation' lawsuit against fellow Cambridge-based firm Dicerna. |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
Chemistry World
October 2, 2006
Bea Perks |
RNAi Pioneers Win Nobel Prize for Medicine Molecular biologists Andrew Fire and Craig Mello have been awarded this year's Nobel prize in physiology or medicine for their discovery of RNA interference. |
The Motley Fool
November 15, 2007
Brian Orelli |
Slowing the Cash Burn Bloody Nose Nastech plans to cut costs following Proctor& Gamble's drop of their osteoporosis drug. Investors, take note. |
Pharmaceutical Executive
April 1, 2006
Patrick Clinton |
Deal Making: Who's Coming to the Table Noteworthy license deals and alliances in the pharmaceutical industry. |
Chemistry World
April 28, 2008
Victoria Gill |
Gene silencing gets fat A team of researchers in the US has developed fat-like nanoparticles that can carry fragments of RNA into cells, bring treatments based on gene silencing a step closer. |
Bio-IT World
December 15, 2004
Samarsky & Welch |
An Unusual Path for RNAi Technology Traditionally, development of novel technologies and research tools follow the basic scientific discoveries. |
Chemistry World
January 31, 2008
John Bonner |
RNAi Scores Victory Against Crohn's Disease in Mice Thousands of people suffering from the debilitating gut condition Crohn's disease could experience relief from their symptoms through a technique that blocks production of a key protein in the inflammation process. |
Bio-IT World
November 2005
Nancy Weil |
Dharmacon, Institutes Form siRNA Global Initiative The company has formed a global alliance with leading biomedical research centers aimed at speeding scientific and medical discoveries now that the first complete siRNA (small interfering RNA) library is available for targeting genes in the human genome. |
The Motley Fool
June 23, 2010
Brian Orelli |
A Novel Drug Technology Worth Watching Regulus signs up another microRNA partner. |
The Motley Fool
February 18, 2011
John Keeling |
An Inside Look at Biotech Investing, Part 2 More on investing in "baby biotechs." |
The Motley Fool
September 21, 2006
Brian Lawler |
Another Partner for Biogen The pharmaceutical enlists help to thwart a troublesome illness. After the market closed yesterday, Biogen added another collaboration agreement with Alnylam Pharmaceuticals to its long list of partners. Investors, take note. |
The Motley Fool
August 24, 2010
Brian Orelli |
Disaster in Medical-Device Land Industry bellwether Medtronic is forecasting a nasty storm. |
